EZH2 and neoplasm: Here, we demonstrate that targeting EZH2 using CRISPR/Cas9 or EPZ6438 results in significant antitumor effects in ATC cells, including reduced cell proliferation, colony formation, invasion and migration in vitro, as well as reduced tumor growth in vivo.